Erythrolar 500mg tablets

Страна: Великобритания

Язык: английский

Источник: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активный ингредиент:

Erythromycin stearate

Доступна с:

Ennogen Pharma Ltd

код АТС:

J01FA01

ИНН (Международная Имя):

Erythromycin stearate

дозировка:

500mg

Фармацевтическая форма:

Oral tablet

Администрация маршрут:

Oral

класс:

No Controlled Drug Status

Тип рецепта:

Valid as a prescribable product

Обзор продуктов:

BNF: 05010500

тонкая брошюра

Artwork No.
Customer
Description
Market
Language
Size
Min. Font Size
Page No.
Version No.
Date
Software
141011/2
Ennogen
Erythromycin Leaflet
UK
English
160 x 330 mm
9 pt
1 of 2
30
16-01-18
Coreldraw 1 2
Packaging Development
Quality Assurance (QA)
Quality Control (QC)
Production
e-mail : [e-mail]
Ph : [phone]
Colours Used
Black
Keyline
ERYTHROLAR (ERYTHROMYCIN) TABLETS 250MG AND 500MG
[Erythromycin]
PACKAGE LEAFLET: INFORMATION FOR THE USER
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START
TAKING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Keep this leaflet. You may need to read it
again.
If you have any further questions, ask your
doctor, pharmacist or nurse.
This medicine has been prescribed for you
only. Do not pass it on to others. It may harm
them, even if their signs of illness are the same
as yours.
If you get any side effects, talk to your doctor,
pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. See section
4.
WHAT IS IN THIS LEAFLET:
1.
WHAT ERYTHROLAR TABLETS ARE AND WHAT THEY
ARE USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE
ERYTHROLAR TABLETS
3.
HOW TO TAKE ERYTHROLAR TABLETS
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE ERYTHROLAR TABLETS
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
Erythrolar Tablets are from the group of medicines
called antibiotics and are useful in the treatment of
and prevention of bacterial infections including:
Infections of the upper respiratory tract i.e.
tonsillitis, pharyngitis, laryngitis, sinusitis and
secondary infections in colds and flu
Infections of the lower respiratory tract i.e.
tracheitis, bronchitis and pneumonia
Mouth infections i.e. gingivitis (inflamed gums)
Eye infections i.e. blepharitis (inflammation of
the eyelids)
Ear infections i.e. otitis media, otitis externa
and mastoiditis
Skin and soft tissue infections
Genito-urinary infections i.e. urethritis,
gonorrhoea, prostatitis
Prophylaxis pre- and post-operative trauma,
burns, rheumatic fever
Other infections such as scarlet

Характеристики продукта

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Erythrolar* (Erythromycin) Tablets 500mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains erythromycin stearate equivalent to erythromycin
BP
500mg.
Excipient with known effect:
Tartrazine (E102) 3.90mg
For the full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablet
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For
the
prophylaxis
and
treatment
of
infections
caused
by
erythromycin
sensitive organisms.
Erythrolar* is effective in the treatment of a great variety a
clinical infections.
1.
Upper
respiratory
tract
infection:
Tonsillitis,
peritonsillar
abscess,
pharyngitis,
laryngitis,
sinusitis,
secondary
infections
in
clods
and
influenza.
2.
Lower respiratory tract infections: Tracheitis, acute and chronic
bronchitis,
pneumonia, bronchiectasis.
3.
Oral infections: Gingivitis, Vincent’s angina.
4.
Eye infections: Blepharitis.
5.
Ear infections: otitis media and otitis externa, mastoiditis.
6.
Skin and soft tissue infections: boils and carbuncles, paronychia,
abscesses,
acne, impetigo, cellulitis, erysipelas.
7.
Prophylazis: pre- and post-operative, trauma, burns, rheumatic fever.
8.
Genito-urinary
infections:
Urethritis,
gonorrhoea,
syphilis,
lymphogranuloma verereum, prostatitis.
9.
Other infections: Osteomyelitis, diphtheria, scarlet fever.
MICROBIOLOGICAL INDICATIONS:
Erythrolar* is active against a wide range of gram-positive
staphylococci,
pneumococci
and
streptococci,
Meningococci,
_Mycoplasma_,
L-forms,
_Haemophilus _
_influenzae_,
agents
causing
trachoma
and
lymphogranuloma
vernereum,
_Chlamydia_,
clostridia,
coryneacteria,
_Neisseria_,
_Treponema _
_pallidum_ and _Bordetella_.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Adults:
1g to 2g/day erythromycin activity divided into 6, 8 or 12 hourly
doses. May
be increased to up to 4g daily in divided doses in severe infections.
Tablets
should be taken before and with meals.
Children:
Normally use Erythrolar* Suspension. If tablets are used calculate
dose on
basis
o